BriaCell Therapeutics (OTC: BCTXF) (TSX.V: BCT) an
immuno-oncology focused biotechnology company with a proprietary targeted
immunotherapy technology, was recently featured on Uptick Newswire’s Stock Day
Podcast. Dr. Bill Williams, BriaCell’s president and CEO, was interviewed for
the podcast by Everett Jolly of Stock Day. Per the interview, Dr. Williams
expressed his enthusiasm regarding the company’s future, as he believes
BriaCell is on the cutting edge of cancer treatment with its effective and safe
immunotherapy applications. Williams also detailed BriaCell’s current major
programs: Bria-IMT, which is in the clinic right now, and Bria-OTS, which is in
development. “BriaCell is developing the first off-the-shelf, personalized
immunotherapy targeting advanced breast cancer,” Dr. Bill Williams, BriaCell’s
president and CEO, stated during the interview. “We have a proprietary
technology that allows us to target immune responses in breast cancer in a
personalized fashion. (The solution) we are working towards is an off-the-shelf
immunotherapy which is very similar in some ways to other successful targeted
personalized immunotherapies that are not off-the-shelf, are costly, and have
been associated with complex manufacturing.”
To listen to the full interview, visit http://ibn.fm/USaQm
To view the full press release, visit http://ibn.fm/2mwWQ
About BriaCell
BriaCell is an immuno-oncology focused biotechnology company
developing targeted and safe approaches for the management of cancer. BriaCell
is currently conducting a Phase I/IIa clinical trial of Bria-IMT, its lead
candidate, in a combination study with pembrolizumab [Keytruda; manufactured by
Merck & Co., Inc.] or ipilimumab [Yervoy; manufactured by Bristol-Myers
Squibb Company]. The combination study is listed in ClinicalTrials.gov as
NCT03328026. BriaCell is developing Bria-OTS, an off-the-shelf personalized
immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments
are personalized to match the patient without the need for personalized
manufacturing. Bria-OTS, which is expected to cover over 90 percent of the
patient population, is designed to produce a potent and selective immune response
against the cancer of each patient while eliminating the time, expense, and
complex manufacturing logistics associated with other personalized
immunotherapies. For more information, visit the company’s website at www.BriaCell.com.
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is committed
to connecting subscribers with companies that have huge potential to succeed in
the short and long-term future. It is part of our mission statement to help the
investment community discover emerging companies that offer excellent growth
potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment